Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
Nanosonics Targets FY27 Revenue Growth as CORIS Launch and AU$40 Million Buyback Advance
Highlights:
Nanosonics Reports FY26 Revenue Growth
Nanosonics Limited (ASX: NAN), an Australian medical technology company specialising in infection prevention, announced its FY26 financial results on 25 August 2026, reporting steady revenue growth alongside progress towards commercialising its CORIS System.
The company recorded annual revenue of AU$203.9 million, marking a 3% increase from the previous financial year, while growth reached 6% after adjusting for currency fluctuations. However, earnings before interest and tax (EBIT) declined 10% to AU$16.0 million, reflecting currency movements and continued investment in business expansion.
Trophon Expansion Strengthens Core Operations
The company's established trophon platform continued supporting operational growth, with several developments highlighting its commercial momentum:
The trophon-only business generated AU$50.6 million in EBIT, increasing 5% year-on-year and reinforcing its importance in financing future innovation.
CORIS Commercialisation Opens New Opportunities
Nanosonics is progressing towards the commercial introduction of its CORIS System, designed to automate flexible endoscope cleaning. Following regulatory milestones across Australia, Europe, the United Kingdom and the United States, the company outlined plans to launch CORIS commercially in the UK, Ireland and Australia during the first half of FY27, followed by the United States. The initiative could diversify revenue streams beyond ultrasound probe disinfection.
FY27 Outlook and Investment Prospects
Nanosonics forecast FY27 revenue between AU$220 million and AU$228 million at constant currency, representing anticipated growth of 8%–12%. The company also announced a new share buyback of up to AU$40 million, supported by AU$155.2 million in cash and a debt-free balance sheet.
Looking ahead, sustained trophon demand and successful CORIS adoption could strengthen long-term growth prospects. However, rising commercialisation expenditure, tariffs and potential margin compression remain important considerations for investors.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au